In 2022, the Office of Inspector General (OIG) and at least two federal courts took a clear stance against pharmaceutical manufacturers' attempts to offer cost-sharing subsidies to Medicare beneficiaries for certain drugs, despite the thoughtful methods by which these subsidies are being offered. OIG's stated concerns are consistently increased risk of fraud, usurpation of the legislative function, and price inflation.